Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma—A retrospective multicenter cohort study

IF 2.3 3区 医学 Q2 HEMATOLOGY European Journal of Haematology Pub Date : 2024-07-31 DOI:10.1111/ejh.14268
Zelal Guel Dilbaz, Sophy Denker, Carla Ankermann, Joerg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Ameya S. Kunte, Sascha Hünecke, Viola Poeschel, Stephan Stilgenbauer, Lorenz Thurner, Il-Kang Na, Moritz Bewarder, Konstantinos Christofyllakis
{"title":"Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma—A retrospective multicenter cohort study","authors":"Zelal Guel Dilbaz,&nbsp;Sophy Denker,&nbsp;Carla Ankermann,&nbsp;Joerg-Thomas Bittenbring,&nbsp;Dominic Kaddu-Mulindwa,&nbsp;Ameya S. Kunte,&nbsp;Sascha Hünecke,&nbsp;Viola Poeschel,&nbsp;Stephan Stilgenbauer,&nbsp;Lorenz Thurner,&nbsp;Il-Kang Na,&nbsp;Moritz Bewarder,&nbsp;Konstantinos Christofyllakis","doi":"10.1111/ejh.14268","DOIUrl":null,"url":null,"abstract":"<p>Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity, and its incidence increases with age. There is a paucity of data regarding use of biweekly R-CHOP (R-CHOP-14) in patients ≥80 years of age. We performed a retrospective cohort study of patients with DLBCL aged ≥80 years treated with R-CHOP-14 and R-miniCHOP in two academic tertiary centers in Germany between 01/01/2005 and 12/30/2019. Overall, 79 patients were included. Median age was 84 years (range 80–91). Despite higher CR rates with R-CHOP-14 (71.4% vs. 52.4%), no statistically significant difference could be found between patients treated with R-CHOP-14 and R-miniCHOP regarding overall survival (OS) (<i>p</i> = .88, HR 0.94, 95% CI = 0.47–1.90) and progression-free survival (PFS) (<i>p</i> = .26, HR 0.66, 95% CI = 0.32–1.36). At a median follow-up of 40 months, the 2-year OS rates were 56% with R-CHOP-14 and 53% with R-miniCHOP. Two-year PFS rates were 46% for R-CHOP-14 and 50% for R-mini-CHOP. Relative dose intensity of chemotherapy did not correlate with OS (<i>p</i> = .72). With the caveat of a retrospective cohort study, we conclude that lacking a difference in OS, R-miniCHOP should be preferred for most patients with untreated DLBCL aged ≥80 years.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"113 5","pages":"675-684"},"PeriodicalIF":2.3000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14268","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14268","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity, and its incidence increases with age. There is a paucity of data regarding use of biweekly R-CHOP (R-CHOP-14) in patients ≥80 years of age. We performed a retrospective cohort study of patients with DLBCL aged ≥80 years treated with R-CHOP-14 and R-miniCHOP in two academic tertiary centers in Germany between 01/01/2005 and 12/30/2019. Overall, 79 patients were included. Median age was 84 years (range 80–91). Despite higher CR rates with R-CHOP-14 (71.4% vs. 52.4%), no statistically significant difference could be found between patients treated with R-CHOP-14 and R-miniCHOP regarding overall survival (OS) (p = .88, HR 0.94, 95% CI = 0.47–1.90) and progression-free survival (PFS) (p = .26, HR 0.66, 95% CI = 0.32–1.36). At a median follow-up of 40 months, the 2-year OS rates were 56% with R-CHOP-14 and 53% with R-miniCHOP. Two-year PFS rates were 46% for R-CHOP-14 and 50% for R-mini-CHOP. Relative dose intensity of chemotherapy did not correlate with OS (p = .72). With the caveat of a retrospective cohort study, we conclude that lacking a difference in OS, R-miniCHOP should be preferred for most patients with untreated DLBCL aged ≥80 years.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
R-CHOP-14和R-mini-CHOP在弥漫大B细胞淋巴瘤老年人中的应用比较--一项回顾性多中心队列研究。
弥漫大 B 细胞淋巴瘤(DLBCL)是最常见的淋巴瘤实体,其发病率随年龄增长而增加。有关≥80岁患者使用双周R-CHOP(R-CHOP-14)的数据很少。我们对 2005 年 1 月 1 日至 2019 年 12 月 30 日期间在德国两个学术三级中心接受 R-CHOP-14 和 R-miniCHOP 治疗的年龄≥80 岁的 DLBCL 患者进行了一项回顾性队列研究。共纳入 79 名患者。中位年龄为84岁(范围为80-91岁)。尽管R-CHOP-14的CR率更高(71.4%对52.4%),但接受R-CHOP-14和R-miniCHOP治疗的患者在总生存期(OS)(p = .88,HR 0.94,95% CI = 0.47-1.90)和无进展生存期(PFS)(p = .26,HR 0.66,95% CI = 0.32-1.36)方面无统计学差异。中位随访时间为 40 个月,R-CHOP-14 的 2 年 OS 率为 56%,R-miniCHOP 为 53%。R-CHOP-14的两年PFS率为46%,R-mini-CHOP为50%。化疗的相对剂量强度与 OS 无关(p = .72)。由于这是一项回顾性队列研究,我们得出结论:由于在OS方面没有差异,对于大多数年龄≥80岁、未经治疗的DLBCL患者来说,R-miniCHOP应该是首选。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
168
审稿时长
4-8 weeks
期刊介绍: European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.
期刊最新文献
TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma. Direct Oral Anticoagulants in Budd-Chiari Syndrome. BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study. The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas. Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1